Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial

Catenacci, DVT; Kang, YK; Park, H; Uronis, HE; Lee, KW; Ng, MCH; Enzinger, PC; Park, SH; Gold, PJ; Lacy, J; Hochster, HS; Oh, SC; Kim, YH; Marrone, KA; Kelly, RJ; Juergens, RA; Kim, JG; Bendell, JC; Alcindor, T; Sym, SJ; Song, EK; Chee, CE; Chao, Y; Kim, S; Lockhart, AC; Knutson, KL; Yen, J; Franovic, A; Nordstrom, JL; Li, D; Wigginton, J; Davidson-Moncada, JK; Rosales, MK; Bang, YJ

Catenacci, DVT (corresponding author), Univ Chicago Med Ctr & Biol Sci, Dept Med, Sect Hematol & Oncol, Chicago, IL 60637 USA.; Catenacci, DVT (corresponding author), Univ Chicago Med Ctr & Biol Sci, Interdisciplinary Gastrointestinal Oncol Program, Chicago, IL 60637 USA.; Catenacci, DVT (corresponding author), Univ Chicago Med Ctr & Biol Sci, Translat Res Comprehens Canc Ctr, Chicago, IL 60637 USA.

LANCET ONCOLOGY, 2020; 21 (8): 1066

Abstract

Background Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate imm......

Full Text Link